The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
Author:
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 VariantNew England Journal of Medicine, 2021
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in EnglandScience, 2021
- A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 VaccinationResearch Square, 2021
- Will AstraZeneca be able to provide clinical trial data on its COVID‐19 vaccine efficacy in older adults?British Journal of Clinical Pharmacology, 2021
- When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccineEuropean Journal of Internal Medicine, 2021
- European countries resume use of AstraZeneca’s COVID-19 vaccine, hoping pause has not dented confidenceScience, 2021
- Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week boosterThe Lancet, 2021
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsThe Lancet, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- The unequal scramble for coronavirus vaccines — by the numbersNature, 2020